查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808646

按產品類型、技術、應用領域和最終用戶分類的治療診斷學市場 - 全球預測 2025-2030

Theranostics Market by Product Type, Technology, Application Area, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計治療診斷學市場規模到 2024 年將達到 29.3 億美元，到 2025 年將達到 33.2 億美元，到 2030 年將達到 63.4 億美元，複合年成長率為 13.72%。

主要市場統計數據
基準年2024年 29.3億美元
預計2025年 33.2億美元
預測年份 2030 63.4億美元
複合年成長率（%） 13.72%

利用診斷和治療的融合，在快速發展的環境中塑造個人化醫療的未來

診療學代表著醫療保健領域的模式轉移，它將診斷精準度與治療效果結合，從而重新定義患者的治療結果。診斷與標靶治療的融合正在推動個人化醫療的發展，使臨床醫生能夠根據分子譜、疾病進展標記和個體反應模式客製化干涉措施。影像學、生物標記和新型藥物傳輸機制的加速融合正在重塑以特異性、數據驅動的路徑為中心的臨床決策。

解鎖重新定義診療解決方案開發和臨床整合的技術和科學突破

在分子影像技術突破、先進生物標記發現以及奈米技術平台廣泛應用的推動下，診療領域正在經歷重大變革時期。放射性藥物偶聯和標靶藥物傳輸等技術創新，正釋放前所未有的機會，實現疾病的精準可視化和治療。隨著次世代定序和機器學習演算法與臨床工作流程的深度融合，診斷檢測的預測能力正在重塑候選治療方案的選擇和給藥方式。

全面評估美國關稅政策對全球供應鏈和治療診斷發展研究動態的影響

美國將於2025年實施關稅，將對全球診療供應鏈造成巨大壓力，尤其是在放射性藥物前驅物和專用診斷劑的採購方面。關鍵原料進口成本的上升，迫使製造商重新評估籌資策略，他們往往轉向區域合作夥伴或進行垂直整合，以保護其營運免受關稅引發的波動影響。同時，研究實驗室正在評估可能在不影響分析性能的情況下提供更優惠成本結構的替代試劑和同位素。

詳細的細分觀點，揭示 Theranossis 產品、技術、應用和最終用戶細分領域的機會和挑戰

在考慮基於產品的細分時，診斷和治療之間的二分法凸顯了不同的創新軌跡。診斷越來越注重能夠檢測微量殘存疾病的高靈敏度分子影像探針，而治療則優先考慮能夠同時進行治療監測和藥物輸送的多功能結構。產品類型之間的這種相互作用形成了一個反饋循環，診斷的改進反映在治療的目標參數中，反之亦然。

解讀影響美洲、歐洲、中東和非洲地區以及亞太地區市場治療診斷解決方案成長的獨特市場促進因素和採用模式

治療診斷學的區域動態體現在不同的採用速度和創新生態系統。美洲地區在分子影像和放射化學領域擁有成熟的基礎設施，並擁有健全的法規環境，鼓勵早期採用伴隨診斷技術。先進的付費模式和學術研究中心的集中，正在推動整合檢測和治療模式的快速應用，尤其是在腫瘤學領域。

聚焦在治療診斷學系統中以顛覆性研發和市場定位推動創新和策略合作的先驅企業

治療診斷學領域的領先機構以其整合跨學科研究能力和策略聯盟的能力而聞名。一些先鋒生物技術和製藥公司正在建立內部放射化學和分子影像部門，以加速早期研發；而診斷創新公司則正在建立聯合開發夥伴關係，將伴隨檢測納入其治療產品線。由此產生的專業知識交叉融合催生了超越傳統器材、診斷和藥品界限的混合經營模式。

為行業領導者制定切實可行的策略路徑，以利用治療診斷學市場的技術進步和監管趨勢

產業領導者應採用協作開發框架，整合診斷和治療研發團隊，以促進無縫銜接的創新路徑。從產品設計早期階段開始的跨職能協作可以最大限度地減少開發重複，加快核准速度，並協調監管參與策略。採用整合的計劃管治結構可以幫助組織確保檢測方法、影像通訊協定和候選治療方案的同步推進。

闡明用於收集、檢驗和綜合治療診斷市場分析中的多維數據的系統研究框架

支撐本分析的研究架構採用多層次方法，以確保穩健性和有效性。二級資訊來源包括同行評審的科學出版物、監管文件和行業白皮書，這些資料為新興技術、政策發展和臨床試驗結果提供了基礎見解。這項案頭研究為識別關鍵趨勢和繪製診療生態系統多個面向的競爭動態奠定了基礎。

整合核心見解，揭示診斷、治療和新興技術之間的協同作用將如何推動個人化醫療的新時代

診斷精準度與治療特異性的融合標誌著個人化醫療的新方向，而治療診斷學正處於這項變革的前沿。核心洞察表明，從增強分子成像到基於奈米技術的遞送系統，各種技術創新正在重新定義疾病檢測和治療的範式。這些進步得益於監理機關對整合核准路徑的積極推動，以及支付方對以結果為導向的報銷模式的興趣。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 個人化醫療的日益普及推動了對治療診斷學的需求
  • 擴大腫瘤治療中診斷與治療的整合
  • 放射性藥物的進展增強了治療診斷學的療效
  • 慢性病增加推動精準醫療方法
  • 分子影像和標靶治療的創新
  • 將治療診斷學應用從腫瘤學擴展到心臟病學和神經病學
  • 製藥公司與診斷公司之間的策略聯盟加速創新
  • 監管支持和簡化的核准流程將推動市場成長
  • 患者對微創和標靶治療方案的需求不斷增加
  • 人工智慧在提高治療診斷學精確度和療效的應用

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章治療診斷學市場（依產品類型）

  • 診斷劑
  • 治療藥物

第9章治療診斷學市場（按技術）

  • 基於生物標記的治療診斷學
  • 伴隨診斷（CDx）
  • 基於基因治療的治療診斷學
  • 分子影像
  • 基於奈米技術的治療診斷學
  • 基於放射性藥物的治療診斷學
  • 靶向藥物輸送

第 10 章治療診斷學市場（按應用）

  • 自體免疫疾病
  • 心血管疾病
  • 感染疾病
  • 發炎性疾病
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤學
    • 乳癌
    • 肺癌
    • 神經內分泌腫瘤
    • 攝護腺癌
    • 甲狀腺癌

第 11 章治療診斷學市場：按最終用戶

  • 診斷影像中心
  • 醫院和癌症護理中心
  • 研究和學術機構
  • 專科診所

第 12 章：美洲治療診斷學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 歐洲、中東和非洲的治療診斷學市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

第 14 章亞太地區的治療診斷學市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Actinium Pharmaceuticals, Inc.
    • Ariceum Therapeutics GmbH
    • Astellas Pharma Inc.
    • BAMF Health
    • Bayer AG
    • bioMerieux SA
    • Biosynth Ltd.
    • Cardinal Health, Inc.
    • Cerebral Therapeutics, Inc.
    • Clarity Pharmaceuticals
    • Curasight A/S
    • Curium Inc.
    • Evergreen Theragnostics, Inc.
    • GE HealthCare Technologies, Inc.
    • Hermes Medical Solutions AB
    • Icon Group
    • Indi Molecular, Inc.
    • Integrated Clinical Oncology Network Pty Ltd.
    • Radiopharm Theranostics Limited
    • Ratio Therapeutics
    • Siemens Healthineers AG
    • SOFIE Co.
    • Telix Pharmaceuticals Limited

第16章 研究人工智慧

第17章 研究統計

第18章 研究聯絡人

第19章 研究報導

第20章 附錄

Product Code: MRR-61081604A0A5

The Theranostics Market was valued at USD 2.93 billion in 2024 and is projected to grow to USD 3.32 billion in 2025, with a CAGR of 13.72%, reaching USD 6.34 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.93 billion
Estimated Year [2025] USD 3.32 billion
Forecast Year [2030] USD 6.34 billion
CAGR (%) 13.72%

Harnessing the Convergence of Diagnostics and Therapeutics to Shape the Future of Personalized Healthcare in a Rapidly Evolving Landscape

Theranostics represents a paradigm shift in healthcare, uniting diagnostic precision and therapeutic efficacy into integrated solutions that promise to redefine patient outcomes. This fusion of diagnostics and targeted treatment is accelerating the movement toward personalized medicine, enabling clinicians to tailor interventions based on molecular profiles, disease progression markers, and individual response patterns. As the confluence of imaging, biomarkers, and novel drug delivery mechanisms gains momentum, the very fabric of clinical decision-making is being rewoven to center on highly specific, data-driven pathways.

In this rapidly evolving landscape, stakeholders across research, regulatory, and commercial domains are rallying around the potential of theranostic platforms to streamline drug development timelines, reduce adverse events, and enhance therapeutic indices. The integration of companion diagnostics with cutting-edge therapeutic agents is laying the groundwork for agile clinical trials and adaptive treatment protocols. Consequently, a growing ecosystem of interdisciplinary collaboration is emerging, fueled by converging expertise in molecular biology, radiology, nanotechnology, and bioinformatics.

Looking ahead, the maturation of theranostic frameworks will hinge on robust partnerships between innovators and healthcare providers, supported by regulatory clarity and reimbursement structures that acknowledge value-based outcomes. As this introduction sets the stage, subsequent sections will delve into transformative shifts, policy impacts, market segmentation, regional dynamics, and strategic imperatives that define the trajectory of theranostic advancements.

Unveiling the Technological and Scientific Breakthroughs Redefining How Theranostic Solutions Are Developed and Integrated Across Clinical Settings

The theranostic landscape is undergoing profound transformation driven by breakthroughs in molecular imaging, advanced biomarker discovery, and the proliferation of nanotechnology-based platforms. Technological innovations such as radiopharmaceutical conjugation and targeted drug delivery vehicles are unlocking unprecedented opportunities to visualize and treat disease loci with pinpoint accuracy. As next-generation sequencing and machine learning algorithms become more deeply entwined with clinical workflows, the predictive power of diagnostic assays is reshaping how therapeutic candidates are selected and administered.

Moreover, regulatory frameworks are progressively adapting to accommodate the dualistic nature of theranostic products. Regulatory agencies are engaging in more frequent stakeholder dialogues to streamline approval pathways, particularly for biomarker-based companion diagnostics. This shift is fostering a more integrated evaluation process that views diagnostics and therapeutics as a unified entity, thereby reducing time-to-market and fostering innovation incentives. At the same time, payers are exploring outcomes-based reimbursement models that reward precision medicine approaches, underscoring the economic rationale for integrated testing and treatment modalities.

From a commercialization standpoint, strategic alliances and in-licensing agreements are proliferating, as pharmaceutical and diagnostic companies seek to co-develop or cross-license complementary assets. These partnerships reflect an industry-wide recognition that no single entity can master the spectrum of capabilities-from advanced imaging instrumentation to molecular assay design and therapeutic formulation-required to deliver holistic theranostic solutions. Ultimately, these transformative shifts are not only redefining product roadmaps but also catalyzing a culture of translational science that bridges laboratory discoveries with bedside impact.

Assessing the Comprehensive Effects of United States Tariff Policies on Global Supply Chains and Research Dynamics in Theranostic Development

The introduction of United States tariffs in 2025 has exerted notable pressure on global theranostic supply chains, particularly in the procurement of radiopharmaceutical precursors and specialized diagnostic reagents. As import costs for key raw materials rise, manufacturers are being compelled to reassess sourcing strategies, often turning to regional partners or pursuing vertical integration to insulate operations from tariff-induced volatility. In parallel, research institutions are evaluating alternative reagents and isotopes that may offer more favorable cost structures without compromising analytical performance.

Amid these dynamics, some stakeholders are intensifying efforts to localize production of essential components, spurred by government incentives aimed at promoting domestic manufacturing capabilities. This localization trend is fostering new collaborations between biotech firms, contract manufacturing organizations, and academic centers to scale up radiochemistry facilities. Although such initiatives entail significant capital investment, the resulting supply chain resilience and reduced exposure to external tariff fluctuations are driving long-term strategic value.

Furthermore, the tariff landscape has precipitated a reevaluation of cross-border clinical trial networks. Sponsors are increasingly factoring in logistical complexities and potential delays when selecting clinical sites, particularly if the movement of diagnostic kits and radiopharmaceuticals is subject to heightened customs scrutiny. These considerations are leading to more geographically diversified trial designs, with a parallel emphasis on harmonizing regulatory requirements and ensuring standardized quality control across multiple jurisdictions. As a result, the cumulative impact of tariffs is reshaping both operational models and strategic frameworks within the theranostic ecosystem.

Mining In-Depth Segmentation Perspectives to Illuminate Opportunities and Challenges Across Theranostic Product, Technology, Application and End-User Tiers

In examining product-based segmentation, the dichotomy between diagnostic agents and therapeutic agents underscores divergent innovation trajectories. Diagnostic agents are increasingly focusing on high-sensitivity molecular imaging probes that can detect minimal residual disease, whereas therapeutic agents are prioritizing multifunctional constructs capable of simultaneous treatment monitoring and drug delivery. This interplay between product types is fostering a feedback loop in which diagnostic refinements inform therapeutic targeting parameters, and vice versa.

The technological segmentation reveals an expansive array of platforms shaping the field. Biomarker-based theranostics are benefiting from next-generation sequencing insights, companion diagnostics are gaining regulatory traction alongside targeted oncology therapies, and gene therapy-based approaches are integrating diagnostic triggers for conditional expression. Molecular imaging enhancements are improving spatial resolution, nanotechnology-based carriers are optimizing pharmacokinetics, radiopharmaceutical-based constructs are evolving with novel isotopes, and targeted drug delivery systems are achieving higher payload specificity. Each of these technological categories interacts synergistically, creating a mosaic of innovation where advances in one domain catalyze progress in another.

Application-area segmentation highlights that oncology remains the nucleus of theranostic deployment, with breast cancer, lung cancer, neuroendocrine tumors, prostate cancer, and thyroid cancer leading research efforts. Concurrently, autoimmune, cardiovascular, infectious, inflammatory, metabolic, and neurological disorders are receiving increasing therapeutic attention as diagnostic modalities become more versatile. Within end-user segmentation, diagnostic imaging centers, hospitals and cancer care centers, research and academic institutes, and specialty clinics are tailoring their service offerings to accommodate integrated test-and-treat protocols. These segments are forging distinct value propositions while leveraging shared technological innovations to address expanding clinical horizons.

Deciphering Unique Regional Drivers and Adoption Patterns Shaping Expansion of Theranostic Solutions Across Americas, EMEA and Asia-Pacific Markets

Regional dynamics in theranostics are characterized by differentiated adoption velocities and innovation ecosystems. In the Americas, established infrastructure for molecular imaging and radiochemistry is complemented by a robust regulatory environment that encourages early adoption of companion diagnostics. Progressive payer models and a high concentration of academic research centers are driving rapid incorporation of integrated test-and-treat paradigms, particularly in oncology.

Meanwhile, Europe, the Middle East & Africa present a heterogeneous landscape marked by pockets of excellence in precision oncology hubs, alongside regions where limited reimbursement frameworks and infrastructure gaps impede widespread deployment. Regulatory harmonization initiatives within the European Union are streamlining cross-border collaboration, while Middle Eastern and North African governments are increasingly investing in specialized facilities to attract clinical research initiatives. Africa's landscape is more nascent but holds promise as diagnostic capabilities expand through public-private partnerships.

In Asia-Pacific, a dynamic convergence of government-led healthcare modernization, a growing middle-income population, and entrepreneurial biotech ecosystems is fueling demand for theranostic solutions. Countries with established nuclear medicine programs are leading in radiopharmaceutical applications, while emerging markets are prioritizing more accessible biomarker-based diagnostics. Collaborative research networks across academic hospitals and industry consortia are laying the groundwork for broad-based adoption, positioning the region as a critical frontier for future growth.

Spotlighting Pioneering Organizations Driving Innovation and Strategic Collaborations in the Theranostics Ecosystem with Disruptive R&D and Market Positioning

Leading organizations in the theranostic domain are distinguished by their ability to integrate multidisciplinary research capabilities with strategic alliances. Several pioneering biotech and pharmaceutical companies are establishing in-house radiochemistry and molecular imaging divisions to accelerate early development, while diagnostic innovators are forging co-development partnerships to embed companion tests within therapeutic pipelines. The resulting cross-pollination of expertise is giving rise to hybrid business models that transcend traditional boundaries between device, diagnostic, and pharmaceutical segments.

Strategic collaborations between academic research institutes and commercial entities are further enriching the innovation landscape. By leveraging academic centers' deep knowledge of disease biology and pharmaceutical companies' development resources, these partnerships are expediting translational research and enabling seamless transition from bench to bedside. In parallel, contract research organizations and contract manufacturing specialists are scaling customized manufacturing processes for complex agents, ensuring regulatory compliance and quality control across global markets.

Investment activity is also influencing company positioning, as venture capital and corporate investors target next-generation platforms such as gene therapy-based theranostics and nanocarrier systems. These inflows are enabling smaller players to challenge incumbents by rapidly advancing niche applications or high-precision diagnostic tools. Collectively, these company-level initiatives underscore a competitive landscape where agility, technical depth, and collaborative acumen determine leadership in the theranostic ecosystem.

Crafting Pragmatic Strategic Pathways for Industry Leaders to Capitalize on Technological Advances and Regulatory Trends in the Theranostics Market

Industry leaders should embrace co-development frameworks that unite diagnostic and therapeutic R&D teams to foster seamless innovation pathways. Embedding cross-functional collaboration at the outset of product design will minimize development redundancies, shorten approval timelines, and align regulatory engagement strategies. By adopting integrated project governance structures, organizations can ensure synchronized advancement of assays, imaging protocols, and therapeutic candidates.

Furthermore, establishing regional manufacturing and distribution hubs can mitigate exposure to supply chain disruptions, including tariff-induced cost pressures. Investing in decentralized radiopharmaceutical production facilities and diversifying sourcing of critical reagents will enhance operational resilience. Concurrently, engaging proactively with reimbursement authorities to demonstrate clinical and economic value through real-world evidence generation will secure favorable coverage policies, unlocking broader patient access.

Finally, leveraging digital platforms and artificial intelligence tools to analyze longitudinal patient data will enable dynamic refinement of theranostic algorithms and personalized treatment pathways. Executives should prioritize partnerships with data analytics providers and invest in interoperable IT infrastructure to drive continuous performance optimization. These actionable steps will empower companies to navigate regulatory complexities, capitalize on technology advances, and cement leadership in the evolving theranostic arena.

Unraveling the Systematic Research Framework Employed to Gather, Validate, and Synthesize Multidimensional Data in Theranostic Market Analysis

The research framework underpinning this analysis employed a multi-tiered approach to ensure robustness and validity. Secondary data sources included peer-reviewed scientific publications, regulatory filings, and industry white papers, which provided foundational insights into emerging technologies, policy developments, and clinical trial outcomes. This desk research laid the groundwork for identifying key trends and mapping competitive dynamics across multiple dimensions of the theranostic ecosystem.

Primary research comprised in-depth interviews with subject-matter experts spanning academic researchers, clinical practitioners, diagnostic developers, and pharmaceutical executives. These interviews yielded qualitative perspectives on development challenges, regulatory nuances, and market adoption barriers. To enhance triangulation, primary responses were cross-verified with publicly available case studies and clinical trial registries, ensuring that interpretations aligned with empirical evidence and real-world outcomes.

Quantitative data analysis involved synthesizing operating metrics, scientific publication trends, and patent filings to gauge innovation trajectories. Data modeling techniques were applied to uncover correlations between technological maturation, regulatory shifts, and adoption rates. The combination of qualitative insights and quantitative validation facilitated a comprehensive view of the theranostic domain, enabling actionable conclusions and strategic recommendations that reflect both current realities and future potential.

Consolidating Core Insights to Highlight How Synergies Between Diagnostics Therapeutics and Emerging Technologies Will Drive the Next Era of Personalized Medicine

The convergence of diagnostic precision and therapeutic specificity is charting a new course for personalized healthcare, with theranostics at the forefront of this transformation. Core insights reveal that technological innovations-from molecular imaging enhancements to nanotechnology-based delivery systems-are redefining disease detection and treatment paradigms. These advancements are supported by regulatory momentum toward integrated approval pathways and payer interest in outcomes-driven reimbursement models.

Segmentation analysis emphasizes the interplay between product types, technology platforms, application areas, and end-user settings, highlighting where value creation opportunities intersect. Regional perspectives underscore the importance of localized infrastructure, regulatory harmonization, and targeted research initiatives in unlocking market potential. Company-level insights further demonstrate that collaborative R&D, agile manufacturing strategies, and strategic investments are critical factors shaping competitive advantage.

In sum, the next era of theranostics will be driven by synergies between diagnostics, therapeutics, and data analytics, fostering a healthcare ecosystem that delivers tailored interventions with improved efficacy and reduced toxicity. Stakeholders who strategically align across scientific, regulatory, and commercial dimensions will be best positioned to translate these synergies into sustainable growth and enhanced patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increasing adoption of personalized medicine driving theranostics demand
  • 5.2. Growing integration of diagnostics and therapeutics in oncology treatment
  • 5.3. Advancements in radiopharmaceuticals enhancing theranostic effectiveness
  • 5.4. Rising prevalence of chronic diseases fueling precision treatment approaches
  • 5.5. Technological innovations in molecular imaging and targeted therapy
  • 5.6. Expanding applications of theranostics beyond oncology into cardiology and neurology
  • 5.7. Strategic collaborations between pharma and diagnostic companies accelerating innovation
  • 5.8. Regulatory support and streamlined approval processes boosting market growth
  • 5.9. Growing patient demand for minimally invasive and targeted treatment solutions
  • 5.10. Emergence of artificial intelligence in improving theranostic accuracy and outcomes

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Theranostics Market, by Product Type

  • 8.1. Introduction
  • 8.2. Diagnostic Agents
  • 8.3. Therapeutic Agents

9. Theranostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Biomarker-Based Theranostics
  • 9.3. Companion Diagnostics (CDx)
  • 9.4. Gene Therapy-Based Theranostics
  • 9.5. Molecular Imaging
  • 9.6. Nanotechnology-Based Theranostics
  • 9.7. Radiopharmaceutical-Based Theranostics
  • 9.8. Targeted Drug Delivery

10. Theranostics Market, by Application Area

  • 10.1. Introduction
  • 10.2. Autoimmune Disorders
  • 10.3. Cardiovascular Diseases
  • 10.4. Infectious Diseases
  • 10.5. Inflammatory Diseases
  • 10.6. Metabolic Disorders
  • 10.7. Neurological Disorders
  • 10.8. Oncology
    • 10.8.1. Breast Cancer
    • 10.8.2. Lung Cancer
    • 10.8.3. Neuroendocrine Tumors
    • 10.8.4. Prostate Cancer
    • 10.8.5. Thyroid Cancer

11. Theranostics Market, by End-User

  • 11.1. Introduction
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals & Cancer Care Centers
  • 11.4. Research & Academic Institutes
  • 11.5. Specialty Clinics

12. Americas Theranostics Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Theranostics Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Theranostics Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Actinium Pharmaceuticals, Inc.
    • 15.3.2. Ariceum Therapeutics GmbH
    • 15.3.3. Astellas Pharma Inc.
    • 15.3.4. BAMF Health
    • 15.3.5. Bayer AG
    • 15.3.6. bioMerieux SA
    • 15.3.7. Biosynth Ltd.
    • 15.3.8. Cardinal Health, Inc.
    • 15.3.9. Cerebral Therapeutics, Inc.
    • 15.3.10. Clarity Pharmaceuticals
    • 15.3.11. Curasight A/S
    • 15.3.12. Curium Inc.
    • 15.3.13. Evergreen Theragnostics, Inc.
    • 15.3.14. GE HealthCare Technologies, Inc.
    • 15.3.15. Hermes Medical Solutions AB
    • 15.3.16. Icon Group
    • 15.3.17. Indi Molecular, Inc.
    • 15.3.18. Integrated Clinical Oncology Network Pty Ltd.
    • 15.3.19. Radiopharm Theranostics Limited
    • 15.3.20. Ratio Therapeutics
    • 15.3.21. Siemens Healthineers AG
    • 15.3.22. SOFIE Co.
    • 15.3.23. Telix Pharmaceuticals Limited

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. THERANOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. THERANOSTICS MARKET: RESEARCHAI
  • FIGURE 24. THERANOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 25. THERANOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 26. THERANOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKER-BASED THERANOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS (CDX), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY GENE THERAPY-BASED THERANOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY MOLECULAR IMAGING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY NANOTECHNOLOGY-BASED THERANOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL-BASED THERANOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THERANOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THERANOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THERANOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THERANOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS & CANCER CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THERANOSTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THERANOSTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 71. AMERICAS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 73. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 75. AMERICAS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 81. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. UNITED STATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. UNITED STATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 84. UNITED STATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 85. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 86. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 87. UNITED STATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 88. UNITED STATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 89. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 90. UNITED STATES THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 91. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 92. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 93. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. CANADA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. CANADA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. CANADA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 97. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 98. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 99. CANADA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. CANADA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 102. CANADA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 103. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. MEXICO THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 105. MEXICO THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 106. MEXICO THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 107. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 108. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 109. MEXICO THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. MEXICO THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 112. MEXICO THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 113. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. BRAZIL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. BRAZIL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. BRAZIL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 118. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 119. BRAZIL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. BRAZIL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 121. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 122. BRAZIL THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 123. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. ARGENTINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. ARGENTINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. ARGENTINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 128. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 129. ARGENTINA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 130. ARGENTINA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 131. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 132. ARGENTINA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED KINGDOM THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 155. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. GERMANY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. GERMANY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. GERMANY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 159. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 160. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 161. GERMANY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GERMANY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 163. GERMANY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 164. GERMANY THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 165. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. FRANCE THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. FRANCE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. FRANCE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 170. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 171. FRANCE THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. FRANCE THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 173. FRANCE THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. FRANCE THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. RUSSIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. RUSSIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. RUSSIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 179. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 180. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 181. RUSSIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. RUSSIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. RUSSIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 184. RUSSIA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 185. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. ITALY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. ITALY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. ITALY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 189. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 190. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 191. ITALY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. ITALY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 193. ITALY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. ITALY THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 195. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. SPAIN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. SPAIN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. SPAIN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. SPAIN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 200. SPAIN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 201. SPAIN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. SPAIN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. SPAIN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 204. SPAIN THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 211. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 213. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED ARAB EMIRATES THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 215. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 220. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 221. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 225. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 230. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 231. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. SOUTH AFRICA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 235. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. DENMARK THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. DENMARK THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. DENMARK THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 240. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 241. DENMARK THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. DENMARK THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 243. DENMARK THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 244. DENMARK THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 245. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NETHERLANDS THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. NETHERLANDS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. NETHERLANDS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 249. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 250. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 251. NETHERLANDS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NETHERLANDS THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 253. NETHERLANDS THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. NETHERLANDS THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 255. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. QATAR THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. QATAR THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. QATAR THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 259. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 260. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 261. QATAR THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. QATAR THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. QATAR THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 264. QATAR THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 265. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. FINLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. FINLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. FINLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 269. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 270. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 271. FINLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. FINLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 273. FINLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. FINLAND THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 275. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. SWEDEN THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. SWEDEN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. SWEDEN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 279. SWEDEN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 280. SWEDEN THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 281. SWEDEN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. SWEDEN THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. SWEDEN THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 284. SWEDEN THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 285. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NIGERIA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. NIGERIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. NIGERIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 289. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 290. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 291. NIGERIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. NIGERIA THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 293. NIGERIA THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 294. NIGERIA THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 295. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EGYPT THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. EGYPT THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. EGYPT THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 299. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 300. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 301. EGYPT THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. EGYPT THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 303. EGYPT THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 304. EGYPT THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 305. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. TURKEY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 307. TURKEY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. TURKEY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 309. TURKEY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 310. TURKEY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 311. TURKEY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. TURKEY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 313. TURKEY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 314. TURKEY THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 315. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. ISRAEL THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 317. ISRAEL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 318. ISRAEL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 319. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 320. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 321. ISRAEL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. ISRAEL THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 323. ISRAEL THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 324. ISRAEL THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 325. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. NORWAY THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. NORWAY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. NORWAY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 329. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 330. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 331. NORWAY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. NORWAY THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 333. NORWAY THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 334. NORWAY THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 335. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. POLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 337. POLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 338. POLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 339. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 340. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 341. POLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. POLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 343. POLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 344. POLAND THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. SWITZERLAND THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. SWITZERLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 350. SWITZERLAND THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 352. SWITZERLAND THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 354. SWITZERLAND THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 355. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 356. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 357. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 358. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 359. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2018-2024 (USD MILLION)
  • TABLE 360. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION AREA, 2025-2030 (USD MILLION)
  • TABLE 361. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 362. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
  • TABLE 363. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 364. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 365. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 366. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 367. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 368. CHINA THERANOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 369. CHINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 370. CHINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)

TAB